Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

These results indicated a significant reduction of CPP from 12 weeks of ZY5301 treatment. Investigators recommended a ZY5301 600 mg/d dose be investigated in a phase 3 trial.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

Femlyv, containing norethindrone acetate and ethinyl estradiol, offers a new oral contraceptive option for individuals with swallowing difficulties, expanding access and convenience.